Articles

Oculomics' is a new frontier in medical science, which is transforming the way we understand and treat ocular and systemic diseases. This innovative approach focuses on the detailed analysis of molecules and structures in the eye, from which information on the health condition of the entire organism can be derived. With the rapid advancement of imaging technologies and through advances in applied research, it will be possible to revolutionise the diagnosis and treatment of many diseases, making increasingly personalised and effective therapies possible.

What is Oculomics

The identification of general problems through the eyes is now an emerging science called "Oculomics', a term coined in 2020 by Prof. Alastair Denniston of the Institute of Inflammation and Ageing in Birmingham.

Professor Denniston himself is among the authors of the study on RETFounda new AI algorithm capable of producing a diagnosis from retinal images.

The retina is, in fact, the only extension of the brain that allows non-invasive examinations of the microvascular structure and functioning of the central nervous system

For example, in the case of RETFound, it is possible to diagnose and prognose both serious eye diseases, such as diabetic retinopathy and glaucoma, and cardiovascular and neurodegenerative diseases, such as heart failure, myocardial infarction, Parkinson's disease or ischaemic stroke.

The eye thus becomes a 'window' through which we can assess our overall health condition. In addition, the non-invasive measurements we can obtain from the eye can be used to give doctors a deeper insight into complex non-eye-related diseases and age-related problems.

Definition and Origins

L'Oculomics is defined as the systematic study of molecules in the eye, including proteins, lipids and metabolites. This scientific discipline arose from the integration of genomics, proteomics and metabolomics, with the aim of better understanding ocular and systemic diseases.

Initially, Oculomics developed thanks to advances in molecular sequencing and analysis technologies. Its origins can be traced back to studies in the early 2000s, when researchers began to see the eye as a microcosm of molecular activity.

Its importance has grown with the accumulation of data, through deep learning algorithms, allowing us to decipher the complexities of different pathologies. This integrated approach offers a unique insight that goes beyond traditional diagnostic methodologies.

Biomarkers

In medical research, Oculomics plays a key role, as it can help identify biomarkers useful to predict the onset of systemic and ocular diseases and to stratify risks in order to develop effective prevention strategies.

Biomarkers are defined as objective parameters useful to predict, verify or diagnose a pathology and to define a treatment programme. The convergence of big data, artificial intelligence and oculomics has resulted in biomarkers that are reliable and sufficiently reproducible to be used in clinical settings.

Advanced Analysis Tools

Advanced analysis tools are at the heart of today's Oculomics. These technologies include mass spectrometry, DNA sequencing and high-resolution imaging.

1. Mass SpectrometryUsed to identify and quantify molecules in eye samples.
2. DNA sequencingIt allows the analysis of genetic variations that could influence general and ocular health.
3. High Resolution ImagingIt provides visual details of ocular structures, facilitating molecular analysis. In particular, OCT, optical coherence tomography, has proved essential.

These instruments allow scientists to collect molecular data with unprecedented precision.

Treatments based on oculomics offer the possibility of intervening specifically on molecular biomarkers associated with particular diseases. This makes it possible to select therapies that act exactly where needed.

Moreover, thanks to oculomics, treatments can be monitored and adapted over time, improving therapeutic efficacy and reducing unwanted side effects.

A concrete example is the use of oculomics in the management of age-related macular degeneration (AMD). With the identification of disease-specific molecular signals, treatments can be more precise.

Finally, the adoption of these technologies in eye treatments improves the quality of life of patients by offering faster and less invasive solutions.

Oculomics: state of the art and perspectives

Current research trends in oculomics focus on the integration of different technologies: from artificial intelligence to big data analysis.

Artificial intelligence is used to analyse large amounts of molecular data, accelerating the discovery of new biomarkers. In addition, big data analysis facilitates the search for correlations between molecules and ocular and systemic diseases.

Currently, the potential of gene therapies is also being explored, using oculomics data to develop treatments that can correct any genetic defects at their root.

Another area of research is the personalisation of treatments. Scientists are trying to use molecular information to create treatments based on individual profiles.

This research is carried out in collaboration with research institutes, pharmaceutical companies and universities, ensuring a multidisciplinary and innovative approach.

Future Challenges and Opportunities

Challenges in the field of oculomics include managing complex data and translating discoveries into clinical practice. However, these challenges also present significant opportunities.

1. Data Management: The amount of data generated requires new methods of storage and analysis.
2. Clinical translation: Converting laboratory findings into practical solutions takes time and collaboration.

Future opportunities include the development of digital platforms that facilitate access to and analysis of oculomics data, making the information more usable for researchers worldwide.

Impact on Health Care

Oculomics has a significant impact on health care, improving diagnosability and clinical efficiency.

Early and Personalised Diagnosis

One of the greatest contributions of oculomics is the possibility of early diagnosis and personalised. Thanks to the early identification of biomarkers, doctors can, in fact, diagnose diseases before clinical signs and symptoms appear.

For example, some diseases that it would be possible to diagnose through retinal biomarkers include:

• neurological diseases, such as multiple sclerosis, Parkinson's disease, Alzheimer's disease, neuromyelitis optica, idiopathic intracranial hypertension, migraine and chiasmatic compression.
• psychiatric disorders, such as schizophrenia, depression, bipolar disorder.
• cardiovascular problems, such as individual systemic risk factors and coronary artery disease
• haematological diseases, such as sickle cell anaemia, thalassaemia, leukaemia
• nutritional deficiency from vitamin D or B12 deficiency
• autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, Bechet's disease,
• infectious or renal diseases
• intoxication by pharmacological agents such as chloroquine, lead, sildenafil and tamoxifen.

Personalisation of therapies based on oculomics means that treatments can be tailored to the specific molecular needs of the patient. This increases the effectiveness of treatments and reduces risks.

In addition, early diagnosis allows more targeted and sustainable treatment pathways to be planned, improving patient adherence to treatment.

Improving Clinical Efficiency

Oculomics contributes to improved clinical efficiency through faster processes and informed decisions. This translates into more efficient healthcare.

• Reducing Diagnosis TimeMolecular analysis allows faster and more accurate diagnoses.
• Targeted Treatments: Personalised therapies reduce the response time to treatment.
• Reducing Errors: The use of accurate data minimises the risk of misdiagnosis.

Clinical efficiency is also increased through the automation of diagnostic processes, which reduces the workload for healthcare personnel and accelerates the delivery of care.

In addition, oculomics supports integrated patient information management, improving communication between different healthcare providers.

This new approach to clinical efficiency helps to reduce overall healthcare costs, making care more accessible and sustainable.

Future of Oculomics

The development prospects for oculomics are promising, with many innovative projects on the horizon.

Firstly, an expansion of molecular analysis technologies is expected. This will allow new biomarkers to be explored and further targeted treatments to be developed.

Furthermore, the integration of artificial intelligence and machine learning could revolutionise the way ophthalmic data are analysed, making processes more efficient.

Another potential development is the expansion of gene therapies to correct molecular defects directly at the source, offering more durable solutions.

Interdisciplinary Collaborations

Interdisciplinary collaborations are essential for the advancement of Oculomics. By combining different competences, more comprehensive and innovative results can be achieved.

1. Shared Search: Collaborations between universities, research institutes and industry stimulate innovation and accelerate progress.
2. Multidisciplinary Approach: Contributions from fields such as molecular biology, computer science and clinical medicine can converge in enriching ophthalmic research.
3. Global Partnerships: Sharing resources and discoveries internationally expands research and development possibilities.

The future of oculomics depends largely on the ability to work together across disciplinary boundaries, leading to significant advances in global health.

These development prospects could radically transform the approach to health care, making oculomics a key component of the medicine of the future.

• Topol, E.J. High-performance medicine: the convergence of human and artificial intelligence. Nat Med 25, 44-56 (2019). https://www.nature.com/articles/s41591-018-0300-7
• Moor, M., Banerjee, O., Abad, Z.S.H. et al. Foundation models for generalist medical artificial intelligence. Nature 616, 259-265 (2023). https://doi.org/10.1038/s41586-023-05881-4
• De Fauw, J., Ledsam, J.R., Romera-Paredes, B. et al. Clinically applicable deep learning for diagnosis and referral in retinal disease. Nat Med 24, 1342-1350 (2018). https://doi.org/10.1038/s41591-018-0107-
• Zhou, Y., Chia, M.A., Wagner, S.K. et al. A foundation model for generalizable disease detection from retinal images. Nature 622, 156-163 (2023). https://doi.org/10.1038/s41586-023-06555